Tech Company Financing Transactions
Nucleonics Funding Round
Nucleonics, based in Langhorne, raised $49.2 million from New Enterprise Associates, Anthem Capital and Burrill & Company.
Transaction Overview
Company Name
Announced On
6/20/2004
Transaction Type
Venture Equity
Amount
$49,200,000
Round
Series B
Investors
Proceeds Purpose
The financing proceeds will also be used to develop a receptor-targeted active delivery system that will let the company expand applications of its eiRNA technology beyond liver diseases to other indications, including the treatment of inflammatory diseases and cancer.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
13 Summit Square Center 305
Langhorne, PA 19047
USA
Langhorne, PA 19047
USA
Phone
Website
Email Address
Overview
Nucleonics is an emerging biotechnology company focused on the development of novel RNA interference-based therapeutics for viral and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Towarnicki
Chief Financial Officer
Richard Fitzgerald
Chief Medical Officer
Michael Young
Vice President
Annette Richter
Browse more venture capital transactions:
Prev: 6/16/2004: Tarari venture capital transaction
Next: 6/21/2004: AmberPoint venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs